Biogen Idec has entered into an agreement to acquire Stromedix, Inc., a privately held biotechnology company, for $75 million in cash and additional payments of as much as $487.5 million based on development milestones across multiple indications focused on new therapies for fibrosis and organ failure. Stromedix was founded by current chief executive officer Michael Gilman, Ph.D. He previously led Biogen Idec’s research organization from 2000 to 2005. Contract Pharma interviewed Dr. Gilman in No...